[go: up one dir, main page]

MA49510A - Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants - Google Patents

Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants

Info

Publication number
MA49510A
MA49510A MA049510A MA49510A MA49510A MA 49510 A MA49510 A MA 49510A MA 049510 A MA049510 A MA 049510A MA 49510 A MA49510 A MA 49510A MA 49510 A MA49510 A MA 49510A
Authority
MA
Morocco
Prior art keywords
isotretinoin
oral
related methods
mucosal formulations
mucosal
Prior art date
Application number
MA049510A
Other languages
English (en)
Inventor
Siew L Chung
Hock S Tan
Original Assignee
Skyline Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyline Biosciences Llc filed Critical Skyline Biosciences Llc
Publication of MA49510A publication Critical patent/MA49510A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA049510A 2017-06-29 2018-06-29 Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants MA49510A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762526743P 2017-06-29 2017-06-29

Publications (1)

Publication Number Publication Date
MA49510A true MA49510A (fr) 2020-05-06

Family

ID=63036329

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049510A MA49510A (fr) 2017-06-29 2018-06-29 Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants

Country Status (14)

Country Link
US (3) US10813880B2 (fr)
EP (2) EP3960155A1 (fr)
JP (1) JP2020526579A (fr)
KR (1) KR20200135931A (fr)
CN (1) CN111032017A (fr)
AU (1) AU2018294318A1 (fr)
CA (1) CA3068310A1 (fr)
EA (1) EA202090164A1 (fr)
IL (1) IL271737A (fr)
MA (1) MA49510A (fr)
MX (1) MX2020000164A (fr)
PH (1) PH12020500032A1 (fr)
SG (1) SG11201912887VA (fr)
WO (1) WO2019006287A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526579A (ja) 2017-06-29 2020-08-31 スカイライン バイオサイエンシズ，エルエルシー イソトレチノイン口腔粘膜製剤及びその使用方法
DE102019135432A1 (de) * 2019-12-20 2021-06-24 Lts Lohmann Therapie-Systeme Ag Lösliche Rückschicht für OTF
US12161755B2 (en) 2020-11-14 2024-12-10 Regents Of The University Of Minnesota Sustained release device for treatment of Parkinson's disease and other disorders
CN113209052B (zh) * 2021-03-16 2022-02-15 深圳市泰力生物医药有限公司 大麻二酚自纳米乳口颊膜制剂及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59232552A (ja) * 1983-06-16 1984-12-27 日東電工株式会社 粘膜包帯
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
JPS63189484A (ja) * 1987-01-30 1988-08-05 Sekisui Chem Co Ltd 口腔粘膜貼付剤用の粘着剤組成物
US4985235A (en) * 1988-08-02 1991-01-15 Kligman Albert M Treatment of periodontoclasia with retinoic acid
US5188817A (en) * 1989-03-27 1993-02-23 Julius Ozick Method of treatment for periodontitis
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
DE60137568D1 (de) * 2000-03-17 2009-03-19 Lg Household & Health Care Ltd Pflaster zum weissen der zähne
CA2423170A1 (fr) 2000-09-22 2002-03-28 Galephar M/F Composition pharmaceutique semi-solide d'isotretinoine
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
CN1829490A (zh) * 2003-07-01 2006-09-06 托德·迈巴赫 包含治疗剂的薄膜
JP4413665B2 (ja) * 2004-03-19 2010-02-10 救急薬品工業株式会社 口腔内粘膜フィルム剤
US20050281757A1 (en) * 2004-06-17 2005-12-22 Sayed Ibrahim Oral care film
MX2007008227A (es) * 2005-01-05 2007-09-11 Novacea Inc Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.
WO2006117803A2 (fr) * 2005-03-14 2006-11-09 Devarajan, Padma, Venkitachalam Systemes d'administration transmucosale de medicaments
US9067082B2 (en) * 2006-07-26 2015-06-30 Ultradent Products, Inc. Dental bleaching compositions having long-term rheological stability and devices, kits and methods that utilize such compositions
US20120046354A1 (en) * 2010-08-18 2012-02-23 Ehrenpreis Eli D Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders
US8241661B1 (en) * 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
WO2013044028A2 (fr) * 2011-09-21 2013-03-28 Texas A&M University System Analogues d'acide mycophénolique comme agents chimiosensibilisants anti-tumoraux
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
CN103319365B (zh) * 2013-06-05 2015-07-08 中国医学科学院皮肤病研究所 一种异维甲酸酰胺衍生物及其制备方法和应用
MA40312A (fr) * 2014-05-29 2017-04-05 Sun Pharmaceutical Ind Ltd Composition pharmaceutique orale d'isotrétinoïne
US10080763B2 (en) * 2015-08-17 2018-09-25 Sidmak Laboratories (India) Pvt. Ltd. Topical film delivery system
JP2020526579A (ja) 2017-06-29 2020-08-31 スカイライン バイオサイエンシズ，エルエルシー イソトレチノイン口腔粘膜製剤及びその使用方法

Also Published As

Publication number Publication date
US20200093735A1 (en) 2020-03-26
CN111032017A (zh) 2020-04-17
EP3644961B1 (fr) 2021-08-04
EP3644961A1 (fr) 2020-05-06
EP3960155A1 (fr) 2022-03-02
JP2020526579A (ja) 2020-08-31
IL271737A (en) 2020-02-27
PH12020500032A1 (en) 2020-09-14
US10813880B2 (en) 2020-10-27
AU2018294318A1 (en) 2020-01-30
KR20200135931A (ko) 2020-12-04
US20200093734A1 (en) 2020-03-26
SG11201912887VA (en) 2020-01-30
EP3644961B9 (fr) 2021-10-13
US10874607B2 (en) 2020-12-29
US20210244656A1 (en) 2021-08-12
WO2019006287A1 (fr) 2019-01-03
CA3068310A1 (fr) 2019-01-03
EA202090164A1 (ru) 2020-05-14
MX2020000164A (es) 2020-07-22

Similar Documents

Publication Publication Date Title
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3436030A4 (fr) Récepteurs chimériques et leurs procédés d'utilisation
EP3377612A4 (fr) Expression fonctionnelle de monooxygénases et procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d'utilisation
EP3878348C0 (fr) Dispositifs médicaux et procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA41951A (fr) Gènes insecticides et procédés d'utilisation
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation
MA53235A (fr) Indoles substitués et procédés d'utilisation associés
MA42409A (fr) Oxystérols et leurs procédés d'utilisation